心血管市場展望

心臟疾病市場上降血壓劑（抗高血壓藥物）的業績在藥劑分類別成為最大，不過，由於學名藥的普及，預料業績額在2017年前將大幅下滑。血脂異常治療藥物的業績額，由於過去曾為世界暢銷藥的Lipitor的獨占權喪失，預料至2017年前將下滑至約82億美元。

本報告，調查心血管市場的概要與市場規模、市場預測、成長牽引因子等，彙整研發產品線、個別藥劑的未來性、上市產品的產品組合、將來預測，由下列摘要形式闡述。

• 報告摘要
• 心血管疾病的概要與流行病學
• 全球市場分析
• 產品線分析
• 競爭情勢
• 心血管疾病的概要與流行病學：摘要
• 高血壓的診斷・治療・管理
• 流行病學
• 血脂異常的診斷・治療・管理
• 發作的診斷・治療・管理
• 流行病學
• 冠狀動脈心臟疾病
• 心衰竭
• 全球市場分析：摘要
• 簡介
• 主要分類・品牌別市場分析
• 市場分析：地區別
• 降血壓劑：簡介
• 降血壓劑的藥劑等級
• 治療指南
• 主要品牌：藥劑等級別
• 主要品牌分析
• 血脂異常治療藥物：簡介
• 血脂異常治療藥物的藥劑等級
• 主要品牌：藥劑等級別
• 主要品牌分析
• 抗血栓劑：簡介
• 抗血栓劑的藥劑等級
• 主要品牌：藥劑等級別
• 主要品牌分析
• 產品線分析：摘要
• 簡介
• 產品線的主要事件
• 心血管產品線概要
• 重度膽固醇過高
• 動脈粥狀硬化
• 心衰竭
• 競爭情勢摘要
• 主要企業的競爭定位
• Pfizer
• 企業概要
• 上市產品種類組合
• R&D產品線分析
• 策略・成長分析
• AstraZeneca
• Bristol-Myers Squibb
• Sanofi
• Merck

Abstract

The cardiovascular market has been crucial in underpinning the fortunes of Big Pharma. Sales have been concentrated in several "mega-blockbuster" brands, but generic competition threatens to substantially reduce the future value of the market.

INTRODUCTION

This report covers antihypertensives, antidyslipidemics, and antithrombotics, which are the three leading categories of cardiovascular therapies by sales. Current and forecast sales of leading established brands in these categories are provided. Growth brands, key drug classes, and leading players through to 2017 are identified. Major pipeline products are profiled including estimated filing year.

FEATURES AND BENEFITS

• Identify growth brands, key drug classes, and leading players through to 2017.
• Review sales forecasts to 2017 for leading products, with analysis of key growth drivers and resistors across the seven major pharmaceutical markets.
• Evaluate the commercial impact of recently completed and ongoing clinical trials.
• Assess the target populations, market potential, and forecast approval dates of major pipeline products.
• Understand the present unmet needs, treatment guidelines, and the epidemiology of cardiovascular disease.

HIGHLIGHTS

Antihypertensives are the largest drug category within the cardiovascular market by sales, but this category will undergo significant value erosion by 2017, principally due to increasing generic competition in the angiotensin receptor blockers class, which accounted for 70% of total antihypertensive sales in 2011

The value of the antidyslipidemic class will fall to around $8.2bn in 2017, partly due to the loss of exclusivity of Lipitor, previously the world's best-selling drug. The availability of generic atorvastatin will halt Crestor sales growth up to loss of exclusivity.

Novel oral anticoagulants are likely to be the fastest growing class of antithrombotics over the forecast period, driven by sales of Boehringer Ingelheim's Pradaxa, Bayer's Xarelto, and Pfizer/Bristol-Myers Squibb's Eliquis.

YOUR KEY QUESTIONS ANSWERED

• How does the market outlook vary for the antihypertensives, antidyslipidemics, and antithrombotics categories up to 2017?
• What are the key growth brands?
• Which were the most important companies in the cardiovascular market in 2011?
• How will the loss of exclusivity of leading brands shape the cardiovascular market, and can pipeline products compensate for these lost sales?
• Which novel therapeutics offer significant potential for future growth?

About the author

• Disclaimer

EXECUTIVE SUMMARY

• Overview and epidemiology of cardiovascular disorders
• Global market analysis
• Pipeline analysis
• Competitive landscape

Overview and epidemiology of cardiovascular diseases

• Summary
• Introduction

• Hypertension
  • Diagnosis, treatment, and management
  • Epidemiology

• Dyslipidemias
  • Diagnosis, treatment, and management
  • Epidemiology

• Stroke
  • Diagnosis, treatment, and management
  • Epidemiology

• Coronary heart disease
• Heart failure

Global market analysis

• Summary
• Introduction

• Key events in the cardiovascular market
  • Pfizer's "house genericLipitor strategy attempts to preserve revenues
  • Tekturna's blockbuster status in doubt following safety concerns
  • Crestor no better than Lipitor in regressing coronary atherosclerosis
  • AIM-HIGH trial results suggest raising HDL-C levels has no clinical benefit
  • Abbott's Trilipix increases the risk of adverse cardiac events in women
  • Vytorin fails to gain CKD indication and FDA adds 80mg simvastatin dose warning

• Market analysis by leading categories and brands
• Market analysis by geography

• Antihypertensives
  • Introduction
  • Antihypertensive drug classes
  • Treatment guidelines
  • Leading brands by drug class
  • Key brand analysis

• Antidyslipidemics
  • Introduction
  • Antidyslipidemic drug classes
  • Leading brands by drug class
  • Key brand analysis

• Antithrombotics
  • Introduction
  • Antithrombotics drug classes
  • Leading brands by drug class
  • Key brand analysis

Pipeline analysis

• Summary
• Introduction

• Key pipeline events
  • Mesoblast's stem cell therapy appears to be safe with promising signals of efficacy
  • Eli Lilly's CETP inhibitor evacetrapib reports encouraging Phase II results
  • Sanofi's anti-PCSK9 enters Phase III development
  • Genentech/BioInvent start GLACIER trial to reduce atherosclerotic plaque

• Cardiovascular pipeline overview
  • HDL-C-raising therapies
  • Severe hypercholesterolemia
  • Atherosclerosis
  • Heart failure

Competitive landscape

• Summary
• Introduction
• Competitive positioning of top companies

• Pfizer
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

• AstraZeneca
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

• Bristol-Myers Squibb
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

• Sanofi
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

• Novartis
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

• Merck
  • Overview
  • Marketed product portfolio
  • R&D pipeline analysis
  • Strategic and growth analysis

Appendix

• Scope and methodology
• Abbreviations

• Bibliography
  • Internet sources

• Table: Classification of hypertension in adults, NICE, 2011
• Table: Global hypertension prevalence (000s), 2012
• Table: Global hypercholesterolemia prevalence (millions), 2012
• Table: Ischemic stroke classification systems
• Table: Types of hemorrhagic stroke
• Table: Global stroke prevalence (cases), 2012
• Table: Global sales of top 20 cardiovascular brands ($m), 2011 and 2017
• Table: Global sales of top 10 antihypertensive drugs ($m), 2011 and 2017
• Table: Global sales of top 10 antidyslipidemic drugs ($m), 2011 and 2017
• Table: Global sales of leading antithrombotic drugs ($m), 2011 and 2017
• Table: Oral HDL-C-raising pipeline drugs
• Table: Parenteral HDL-C-raising pipeline drugs
• Table: Severe hypercholesterolemia pipeline drugs
• Table: Anti-inflammatory (atherosclerosis) pipeline drugs
• Table: Heart failure pipeline drugs
• Table: Pfizer sales of leading cardiovascular brands ($m), 2011
• Table: AstraZeneca sales of leading cardiovascular brands ($m), 2011
• Table: Bristol-Myers Squibb sales of leading cardiovascular brands ($m), 2011
• Table: Sanofi sales of leading cardiovascular brands ($m), 2011
• Table: Novartis sales of leading cardiovascular brands ($m), 2011
• Table: Merck sales of leading cardiovascular brands ($m), 2011
• Table: Merck late-stage cardiovascular pipeline, 2011

• Figure: Types of lipoproteins
• Figure: Global cardiovascular sales, by category ($m), 2011 - 17
• Figure: Global cardiovascular sales, by geographic region ($m), 2011 - 17
• Figure: Antihypertensive prescriptions in England, by class (000s), 2004 - 10
• Figure: Angiotensin-II receptor blocker prescriptions in England (000s), 2004 - 10
• Figure: Global antihypertensive sales, by class ($m), 2011 - 17
• Figure: Statin prescriptions in England, by molecule (000s), 2004 - 10
• Figure: Global antidyslipidemic sales, by class ($m), 2011 - 17
• Figure: Global antithrombotics sales, by class ($m), 2011 - 17
• Figure: Key pipeline compounds and forecast filing dates
• Figure: Global cardiovascular sales, by company ($m), 2011 - 17
• Figure: Global sales decline of 10 leading brands ($m), 2017
• Figure: Pfizer cardiovascular sales, by brand ($m), 2011 - 17
• Figure: AstraZeneca cardiovascular sales, by brand ($m), 2011 - 17
• Figure: Bristol-Myers Squibb cardiovascular sales, by brand ($m), 2011 - 17
• Figure: Sanofi cardiovascular sales, by brand ($m), 2011 - 17
• Figure: Novartis cardiovascular sales, by brand ($m), 2011 - 17
• Figure: Merck cardiovascular sales, by brand ($m), 2011 - 17